tetrandrine
Tetrandrine, isolated from the root of Stephania tetrandra S Moore, is a traditional Chinese clinical agent for silicosis, autoimmune disorders, inflammatory pulmonary diseases, cardiovascular diseases and hypertension. Tetrandrine is a potent MDR-reversing agent and is an ABCB1/ABCC1 inhibitor. Tetrandrine (CBT-1) is being developed by CBA Pharma, as an adjunctive therapy to chemotherapy in various cancer types with multiple drug resistance (MDR), including acute myelogenous leukemia , Breast, Non-Hodgkin’s Lymphoma, Hodgkin’s disease, Non-Small Cell Lung Cancer, Multiple Myeloma, Gallbladder, Pancreatic, Gastrointestinal Tract, Small Cell Lung Cancer, Bladder, Head & Neck, and Sarcoma. — NCATS
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Mar 5, 2020 (NCT04308317)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Multidrug resistance protein 3INHIBITOR
ABCB4 inhibitor
CACNA1C inhibitor
Chemistry & pharmacology
SMILES
COC1=CC=C2C[C@@H]3N(C)CCC4=C3C(OC5=CC6=C(CCN(C)[C@H]6CC7=CC=C(OC1=C2)C=C7)C=C5OC)=C(OC)C(OC)=C4- Mol. weight
- 622.7499 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTetrandrine ↗
- NCATS29EX23D5AJ ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05697029 | Phase 4 | Dec 31, 2023 | Peking University |
| NCT05245448 | N/A | Feb 22, 2022 | Peking University |
| NCT04308317 | Phase 4 | Mar 5, 2020 | Henan Provincal People's Hospital |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Henan Provincal People's Hospital | Academic/Hospital | 1 | 1 | 1 | 2020 |